Last reviewed · How we verify

Anti-PD-L1 antibody atezolizumab

Gustave Roussy, Cancer Campus, Grand Paris · Phase 2 active Small molecule

Anti-PD-L1 antibody atezolizumab is a PD-L1 inhibitor Small molecule drug developed by Gustave Roussy, Cancer Campus, Grand Paris. It is currently in Phase 2 development for Non-small cell lung cancer, Urothelial carcinoma, Triple-negative breast cancer.

Atezolizumab blocks the PD-L1 checkpoint protein on tumor cells, preventing it from suppressing anti-tumor immune responses and allowing T cells to attack cancer.

Atezolizumab blocks the PD-L1 checkpoint protein on tumor cells, preventing it from suppressing anti-tumor immune responses and allowing T cells to attack cancer. Used for Non-small cell lung cancer, Urothelial carcinoma, Triple-negative breast cancer.

At a glance

Generic nameAnti-PD-L1 antibody atezolizumab
SponsorGustave Roussy, Cancer Campus, Grand Paris
Drug classPD-L1 inhibitor
TargetPD-L1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Atezolizumab is a monoclonal antibody that binds to programmed death ligand 1 (PD-L1) on the surface of tumor cells and immune cells. By blocking the PD-L1/PD-1 interaction, it removes a key immune evasion mechanism that cancers use to hide from the immune system. This restores T cell activation and proliferation, enabling the body's own immune system to recognize and eliminate cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Anti-PD-L1 antibody atezolizumab

What is Anti-PD-L1 antibody atezolizumab?

Anti-PD-L1 antibody atezolizumab is a PD-L1 inhibitor drug developed by Gustave Roussy, Cancer Campus, Grand Paris, indicated for Non-small cell lung cancer, Urothelial carcinoma, Triple-negative breast cancer.

How does Anti-PD-L1 antibody atezolizumab work?

Atezolizumab blocks the PD-L1 checkpoint protein on tumor cells, preventing it from suppressing anti-tumor immune responses and allowing T cells to attack cancer.

What is Anti-PD-L1 antibody atezolizumab used for?

Anti-PD-L1 antibody atezolizumab is indicated for Non-small cell lung cancer, Urothelial carcinoma, Triple-negative breast cancer, Other solid tumors (phase 2 evaluation).

Who makes Anti-PD-L1 antibody atezolizumab?

Anti-PD-L1 antibody atezolizumab is developed by Gustave Roussy, Cancer Campus, Grand Paris (see full Gustave Roussy, Cancer Campus, Grand Paris pipeline at /company/gustave-roussy-cancer-campus-grand-paris).

What drug class is Anti-PD-L1 antibody atezolizumab in?

Anti-PD-L1 antibody atezolizumab belongs to the PD-L1 inhibitor class. See all PD-L1 inhibitor drugs at /class/pd-l1-inhibitor.

What development phase is Anti-PD-L1 antibody atezolizumab in?

Anti-PD-L1 antibody atezolizumab is in Phase 2.

What are the side effects of Anti-PD-L1 antibody atezolizumab?

Common side effects of Anti-PD-L1 antibody atezolizumab include Fatigue, Immune-related pneumonitis, Immune-related hepatitis, Immune-related colitis, Rash, Hypothyroidism.

What does Anti-PD-L1 antibody atezolizumab target?

Anti-PD-L1 antibody atezolizumab targets PD-L1 and is a PD-L1 inhibitor.

Related